Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: Adv Drug Deliv Rev. 2023 Mar 17;196:114776. doi: 10.1016/j.addr.2023.114776

Fig. 6. Examples of fungal burden and survival studies employing DectiSomes.

Fig. 6.

(A). DEC2-AmB-LLs significantly reduced the fungal burden of C. albicans in the kidneys in an invasive candidiasis model relative to control AmB-LLs. (B). DEC2-AmB-LLs significantly reduced the fungal burden of A. fumigatus in the lungs in a pulmonary aspergillosis mouse model. (C). DEC2-AmBisome significantly reduced the fungal burden of C. albicans in the kidneys relative to AmBisome® in an invasive candidiasis mouse model. (D). DEC2-AmB-LLs significantly improved the survival of mice with invasive candidiasis relative to AmB-LLs. (E). DEC2-AmB-LLs significantly improved the survival of mice with pulmonary aspergillosis. (D & E). The % surviving mice is plotted vs days post-infection and mice were liposome treated on day 0 and day 1 respectively. One or two doses of DectiSomes and AmB-LLs delivering 0.2 mg AmB/kg mouse wight were used in each experiment. Buffer controls represent infected animals mock treated. A, C, D, E. Neutropenic immunosuppression mouse models. B. A steroid immunosuppression mouse model. A. B. C. PMW is the Mann-Whitney P test for non-parametric data. PGPW is the Gehan-Breslow-Wilcoxon P test of survival data. The data are from replicate experiments of those not shown in the original publications [215,218,219,274].